AbbVie Nears $10.9 Billion Acquisition of Apogee Therapeutics

AbbVie (ABBV) is closing in on a deal to acquire Apogee Therapeutics for $10.9 billion in cash, according to a Reuters report citing people familiar with the matter in the Financial Times. The price values Apogee at a roughly 60% premium to its closing share price on Thursday, June 18.

Deal Details

• Total Value: $10.9 billion in cash
• Premium: Approximately 60% above the June 18 closing price
• Payment Method: All cash
• Target: Apogee Therapeutics, a biotech firm focused on immunology treatments

Rationale for the Deal

This acquisition is part of AbbVie's strategy to bolster its pipeline, particularly in immunology. Apogee is believed to have promising drug candidates that could complement AbbVie's existing portfolio. The deal would be AbbVie's largest since its 2019 acquisition of Allergan.

Regulatory Challenges

The deal is expected to undergo antitrust review. Neither AbbVie nor Apogee has disclosed details regarding regulatory approvals or the expected closing timeline.

Impact on Stocks

No immediate reaction from AbbVie's stock (ABBV) has been reported. Analysts may view the deal positively if it enhances future growth, though the high premium could raise questions about return on investment.